Mudgal Varchasvi, Mishra Saloni, Gupta Upma, Bagul Koustubh R
Psychiatry, Mahatma Gandhi Memorial Medical College, Indore, IND.
Physiology, Netaji Subhash Chandra Bose Medical College, Jabalpur, Jabalpur, IND.
Cureus. 2025 May 31;17(5):e85131. doi: 10.7759/cureus.85131. eCollection 2025 May.
Background Treatment-resistant obsessive-compulsive disorder (tr-OCD) remains a significant clinical challenge, as many patients fail to respond to conventional serotonergic therapies despite multiple augmentation strategies. Emerging evidence from neurobiological research suggests that dopaminergic dysfunction, particularly in the prefrontal cortex, may contribute to the persistence of OCD symptoms. The objective of this study was to evaluate the efficacy and tolerability of methylphenidate (MPH), a dopamine and norepinephrine reuptake inhibitor, as an adjunct in patients with tr-OCD. Methodology This case series examines six individuals with tr-OCD who remained symptomatic despite adequate trials of first-line selective serotonin reuptake inhibitors (SSRIs) and various augmentation strategies. MPH was introduced as an adjunct to their existing pharmacotherapy regimens. Clinical outcomes were assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and during follow-up over several weeks, with additional clinical judgment supporting therapeutic decisions. Results All six patients demonstrated significant clinical improvement following MPH augmentation. The mean baseline Y-BOCS score was 27.4, which reduced to a mean post-treatment score of 15.1, representing a mean reduction of 12.3 points. Reductions in obsessive thoughts and compulsive behaviors were observed, alongside improvements in cognitive flexibility and impulse control. The treatment was generally well-tolerated, with no serious adverse effects reported. Conclusion These preliminary findings suggest that dopaminergic augmentation with MPH may offer therapeutic benefits in cases of tr-OCD. The observed improvements support the hypothesis that enhancing prefrontal dopamine availability can positively influence OCD symptomatology. Further randomized controlled trials are necessary to confirm these results, define optimal dosing strategies, and establish long-term safety and efficacy.
背景
难治性强迫症(tr-OCD)仍然是一项重大的临床挑战,因为尽管采取了多种增效策略,但许多患者对传统的血清素能疗法没有反应。神经生物学研究的新证据表明,多巴胺能功能障碍,尤其是前额叶皮质的功能障碍,可能导致强迫症症状持续存在。本研究的目的是评估哌醋甲酯(MPH),一种多巴胺和去甲肾上腺素再摄取抑制剂,作为tr-OCD患者辅助治疗的疗效和耐受性。
方法
本病例系列研究了6例tr-OCD患者,尽管他们接受了充分的一线选择性5-羟色胺再摄取抑制剂(SSRIs)试验和各种增效策略,但仍有症状。MPH被引入作为他们现有药物治疗方案的辅助药物。在基线和数周的随访期间,使用耶鲁-布朗强迫症量表(Y-BOCS)评估临床结果,并通过额外的临床判断支持治疗决策。
结果
所有6例患者在MPH增效治疗后均表现出显著的临床改善。Y-BOCS评分的平均基线值为27.4,治疗后平均降至15.1,平均降低了12.3分。观察到强迫观念和强迫行为减少,同时认知灵活性和冲动控制得到改善。该治疗总体耐受性良好,未报告严重不良反应。
结论
这些初步研究结果表明,MPH进行多巴胺能增效治疗可能对tr-OCD患者有益。观察到的改善支持了这样的假设,即提高前额叶多巴胺水平可以对强迫症症状产生积极影响。需要进一步的随机对照试验来证实这些结果,确定最佳给药策略,并确立长期安全性和疗效。